Abstract:Background: The seasonal influenza vaccine coverage rate in China is only 1.9 %. There is no information available on the economic burden of influenza-associated outpatient visits and hospitalizations at the national level, even though this kind of information is important for informing national-level immunization policy decision-making. Methods: A retrospective telephone survey was conducted in 2013/14 to estimate the direct and indirect costs of seasonal influenza-associated outpatient visits and hospitalizations from a societal perspective. Study participants were laboratory-confirmed cases registered in the National Influenza-like Illness Surveillance Network and Severe Acute Respiratory Infections Sentinel Surveillance Network in China in 2013. Patient-reported costs from the survey were validated by a review of hospital accounts for a small sample of the inpatients. Results: The study enrolled 529 outpatients (median age: eight years; interquartile range [IQR]: five to 20 years) and 254 inpatients (median age: four years; IQR: two to seven years). Among the outpatients, 22.1 % (117/529) had underlying diseases and among the inpatients, 52.8 % (134/254) had underlying diseases. The average total costs related to influenza-associated outpatient visits and inpatient visits were US$ 155 (standard deviation, SD US$ 122) and US$ 1,511 (SD US$ 1,465), respectively. Direct medical costs accounted for 45 and 69 % of the total costs related to influenza-associated outpatient and inpatient visits, respectively. For influenza outpatients, the mean cost per episode in children aged below five years (US$ 196) was higher than that in other age groups (US$ 129-153). For influenza inpatients, the mean cost per episode in adults aged over 60 years (US$ 2,735) was much higher than that in those aged below 60 years (US$ 1,417-1,621). Patients with underlying medical conditions had higher costs per episode than patients without underlying medical conditions (outpatients: US$ 186 vs. US$ 146; inpatients: US$ 1,800 vs. US$ 1,189). In the baseline analysis, inpatients reported costs were 18 % higher than those found in the accounts review (n = 38). Conclusion: The economic burden of influenza-associated outpatient and inpatient visits in China is substantial, particularly for young children, the elderly, and patients with underlying medical conditions. More widespread influenza vaccination would likely alleviate the economic burden of patients. The actual impact and cost-effectiveness analysis of the influenza immunization program in China merits further investigation.

Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting

Cost-of-illness comparison between clinical judgment and molecular point-of-care testing for influenza-like illness patients in Germany

Cost-effectiveness study on influenza prevention in Hong Kong

Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward

Cost-effectiveness of Quadrivalent Versus Trivalent Influenza Vaccine for Elderly Population in China.

The need for strengthening the influenza virus detection ability of hospital clinical laboratories: an investigation of the 2009 pandemic

Single centre experience: Managing seasonal influenza without a point-of-care test

Implementation of influenza point-of-care testing and patient cohorting during a high-incidence season: a retrospective analysis of impact on infection prevention and control and clinical outcomes

A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses

[Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].

The Effectiveness of Influenza Vaccine among Elderly Chinese: A Regression Discontinuity Design Based on Yinzhou Regional Health Information Platform

Cost-effectiveness of Introducing National Seasonal Influenza Vaccination for Adults Aged 60 Years and above in Mainland China: a Modelling Analysis

The economic burden of influenza-associated outpatient visits and hospitalizations in China: a retrospective survey

[Cost-Effectiveness Analysis of Quadrivalent Influenza Vaccination for Older Adults Aged 60 and above in Mainland China].

Modeling the potential impacts of outpatient antiviral treatment in reducing influenza-associated hospitalizations in the United States

Effectiveness of influenza vaccine among the population in Chongqing, China, 2018–2022: A test negative design-based evaluation

Influenza vaccination for heart failure patients: a cost-effectiveness analysis from the perspective of Chinese healthcare system

Economic and operational impact of an improved pathway using rapid molecular diagnostic testing for patients with influenza-like illness in a German emergency department

Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample

Cost-effectiveness of seasonal influenza vaccination of children in China: a modeling analysis

A Multicentre, Randomized, Controlled Trial of Oseltamivir in the Treatment of Influenza in a High-Risk Chinese Population